Investigational drug · Phase 3
HRS-1893
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obstructive Hypertrophic Cardiomyopathy, Heart Failure With Preserved Ejection Fraction, Hypertrophic Cardiomyopathy.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
12
Any phase or sponsor naming "HRS-1893"
First trial start
2024
Aug 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-1893", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obstructive Hypertrophic Cardiomyopathy
- Heart Failure With Preserved Ejection Fraction
- Hypertrophic Cardiomyopathy
- Non-obstructive Hypertrophic Cardiomyopathy
Approved drugs for the same conditions: Heart failure · Hypertrophic cardiomyopathy · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-1893" as an intervention, largest first.
- A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic CardiomyopathyRecruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07021963 · 300 participants (planned) · Start Jul 4, 2025 · Primary completion Dec 2027
Drug: HRS-1893 Tablet · For: Hypertrophic Cardiomyopathy
Sites: Beijing, China
- A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic CardiomyopathyPivotal-lookingActive, not recruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07021976 · 228 participants · Start Aug 11, 2025 · Primary completion Sep 2026
Drug: HRS-1893 Tablets; HRS-1893 Placebo Tablets · For: Obstructive Hypertrophic Cardiomyopathy
Sites: Beijing, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06816251 · 84 participants · Start Feb 25, 2025 · Primary completion Nov 18, 2025
Drug: HRS-1893; HRS-1893 placebo · For: Non-obstructive Hypertrophic Cardiomyopathy
Sites: Beijing, China
- A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic CardiomyopathyCompleted
Shandong Suncadia Medicine Co., Ltd.Industry
NCT05879523 · 76 participants · Start Jun 5, 2023 · Primary completion Mar 21, 2024
Drug: HRS-1893; Placebo · For: Obstructive Hypertrophic Cardiomyopathy
Sites: Beijing, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07479641 · 58 participants · Start Apr 14, 2026 · Primary completion Sep 14, 2026
Drug: Test formulation of HRS-1893 tablet; Reference formulation of HRS-1893 tablet · For: Cardiomyopathy
Sites: Beijing, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07269717 · 48 participants (planned) · Start Mar 30, 2026 · Primary completion Mar 2027
Drug: HRS-1893 Tablet; HRS-1893 Tablet Placebo · For: Heart Failure With Preserved Ejection Fraction
Sites: Shanghai, China
- A Trial of HRS-1893 in Patients With Obstructive Hypertrophic CardiomyopathyActive, not recruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06516068 · 42 participants · Start Aug 11, 2024 · Primary completion Nov 18, 2024
Drug: HRS-1893 · For: Obstructive Hypertrophic Cardiomyopathy
Sites: Beijing, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07272330 · 38 participants · Start Dec 11, 2025 · Primary completion Mar 21, 2026
Drug: HRS-1893 tablet A; HRS-1893 tablet B · For: Cardiomyopathy
Sites: Beijing, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06775834 · 24 participants · Start Feb 11, 2025 · Primary completion Jul 23, 2025
Drug: HRS-1893 · For: Hypertrophic Cardiomyopathy
Sites: Chengdu, China
Atridia Pty Ltd.Industry
NCT07033455 · 20 participants · Start Jun 25, 2025 · Primary completion Sep 5, 2025
Drug: HRS-1893 · For: Hypertrophic Cardiomyopathy
Sites: Nedlands, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS-1893, a cardiac myosin inhibitor, in healthy subjects.
Yang K, Liu W, Lin Y, et al. · Br J Clin Pharmacol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.